Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs

Lancet Neurology

Volumn 2, Issue 6, 2003, Pages 347-356

  Patsalos, Philip N ^a   Perucca, Emilio ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORAMPHENICOL; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DIGOXIN; DOCETAXEL; ETIRACETAM; FELBAMATE; FLUVOXAMINE; FURAFYLLINE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MICONAZOLE; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BRAIN DISEASE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EPILEPSY; HEMOCONCENTRATION; HUMAN; INHIBITION KINETICS; LIVER METABOLISM; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INDUCTION; EPILEPSY; HUMANS; ISOENZYMES;

EID: 0038196961     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00409-5     Document Type: Review

References (144)

1. Beghi E., Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties and perspectives for future research. Drugs. 49:1995;680-694.
2. Patsalos P.N., Froscher W., Pisani F., van Rijn C. The importance of drug interactions in epilepsy therapy. Epilepsia. 43:2002;365-385.
3. Patsalos P.N. Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions. Seizure. 3:1994;163-170.
4. Patsalos P.N., Duncan J.S. Antiepileptic drugs: A review of clinically significant drug interactions. Drug Safety. 9:1993;156-184.
5. Patsalos P.N. Pharmacokinetic and pharmacodynamic interactions: Principles and interpretative pitfalls. Epileptologia. 6:(suppl 2):1998;9-19.
6. Bauer L.A. Interference of oral phenytoin absorption by continuous nasogastric feeding. Neurology. 32:1982;570-572.
7. Hatton R.C. Dietery interaction with phenytoin. Clin Pharm. 3:1984;110-111.
8. Worden J.P. Jr, Wood C.A. Jr, Workman C.H. Phenytoin and nasogastric feedings. Neurology. 34:1984;132.
9. Lin J.H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet. 42:2003;59-98.
10. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 97:2000;3473-3478.
11. Fricker G., Drewe J., Huwyler J. Gutmann H, Begninger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporine A: in vitro-in vivo correlation. Br J Pharmacol. 118:1996;1841-1847.
12. Lown K.S., Mayo R.R., Leichtman A.B., et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin. Clin Pharmacol Ther. 62:1997;248-260.
13. Meerum Terwgot J.M., Malingre M.M., Beijnen J.H., et al. Co-administration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 5:1999;3379-3384.
14. Malingre M.M., Richel D.J., Beijnen J.H., et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of decetaxel. J Clin Oncol. 19:2001;1160-1166.
15. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport. 12:2001;3557-3560.
16. Rizzi M., Caccia S., Guiso G., et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci. 22:2002;5833-5839.
17. Potschka H., Loscher W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport. 12:2001;2387-2389.
18. Potschka H., Fedrowitz M., Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett. 327:2002;173-176.
19. Sisodiya S.M. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol. 16:2003;197-201.
20. Cox D.S., Scott K.R., Gao H., Eddington N.D. Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther. 302:2002;1096-1104.
21. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 13:1995;129-134.
22. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulated these proteins in human carcinoma cells. Mol Pharmacol. 49:1996;311-318.
23. Jette L., Beaulieu E., Leclerc J.M., Beliveau R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol. 270:1996;F756-F765.
24. Verschraagen M., Koks C.H.W., Schellens J.H.M., Beijnen J.H. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res. 40:1999;301-306.
25. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol. 15:2001;405-417.
26. Von Moltke L.L., Greenblatt D.J., Schmider J., Wright C.E., Harmatz J., Schader R.I. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol. 55:1998;113-122.
27. Rolan P.E. Plasma protein binding displacement interactions: Why are they still regarded as clinically important? Br J Clin Pharmacol. 37:1994;125-128.
28. Sansom L.N., Evans A.M. What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety. 12:1995;227-233.
29. Benet L.Z., Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 71:2002;115-121.
30. Patsalos P.N. Therapeutic drug monitoring in epilepsy: principles and concepts. Epilepsy Monit. 5:2001;1-6.
31. Patsalos P.N. Therapeutic drug monitoring in epilepsy: the established and the new antiepileptic drugs. Epilepsy Monit. 6:2002;1-8.
32. Perucca E., Hebdige S., Frigo G.M., Gatti G., Lecchini S., Crema A. Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects. Clin Pharmacol Ther. 28:1980;779-789.
33. Patsalos P.N., Lascelles P.T. Effect of sodium valproate on plasma protein binding of diphenylhydantoin. J Neurol Neurosurg Psychiat. 40:1977;570-574.
34. Tsanaclis L.M., Allen J., Perucca E., Routledge P.A., Richens A. Effect of valproate on free plasma phenytoin concentrations. Br J Clin Pharmacol. 18:1984;17-20.
35. Patsalos P.N., Lascelles P.T. In vitro hydroxylation of diphenylhydantoin and its inhibition by other commonly used anticonvulsants. Biochem Pharmacol. 26:1977;1929-1933.
36. Riva R., Albani F., Contin M., et al. Time-dependent interaction between phenytoin and valproic acid. Neurology. 35:1985;510-515.
37. Patsalos P.N., Elyas A.A., Ratnaraj N., Iley J. Concentration-dependent displacement of tiagabine by valproic acid. Epilepsia. 43:(suppl 8):2002;143.
38. Anderson G.D. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 32:1998;554-563.
39. Spina E, Perucca E, Levy RH. Predictability of metabolic antiepileptic drug interactions. In: Majkowski J, Bourgeois B, Patsalos PN, Mattson RH, eds. Antiepileptic drug: combination therapy and interactions. Cambridge: Cambridge University Press, (in press).
40. Perucca E., Hedges A., Makki K.A., Ruprah M., Wilson J.F., Richens A. A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol. 18:1984;401-410.
41. Su T., He W., Gu J., Lipinskas T.W., Ding X. Differential xenobiotic induction of CYP2A5 in mouse liver, kidney, lung, and olfactory mucosa. Drug Metab Dispos. 26:1998;822-824.
42. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther. 33:1987;139-144.
43. Patsalos P.N., Duncan J.S., Shorvon S.D. Effect of the removal of antiepileptic drugs on antipyrine kinetics in patients taking polytherapy. Br J Clin Pharmacol. 26:1988;253-259.
44. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 29:1997;413-580.
45. Green M.D., Bishop W.P., Tephley T.R. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Disp. 23:1995;299-302.
46. Bonate P.L., Reith K., Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet. 34:1998;375-404.
47. Powell J.R., Nelson E., Conrad K.A., Likes K., Byers J. I.I.I., Perrier D. Phenobarbital clearance, elimination with alkaline diuresis, and bioavailability in adults. Clin Pharmacol Ther. 29:1981;273.
48. Perucca E., Levy R.H. Combination therapy and drug interactions. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. Antiepileptic Drugs. 5th edn:2002;96-102 Lippincott Williams and Wilkins, Philadelphia.
49. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 41:2000;1597-1607.
50. Anderson G.D. Children versus adults: Pharmacokinetic and adverse-effect differences. Epilepsia. 43:(suppl 3):2002;53-59.
51. Stewart C.F., Hampton E.M. Effect of maturation on drug disposition in pediatric patients. Clin Pharm. 6:1987;548-564.
52. Morselli P.L., Franco-Morselli R., Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet. 5:1980;485-527.
53. Dalton G.J. Developmental aspects of drug conjugation with special reference to glucuronidation. Ann Rev Pharmacol Toxicol. 18:1978;17-35.
54. Suzuki Y., Cox S., Hayes J., Walson P.D. Valproic acid dosage necessary to maintain therapeutic concentrations in children. Ther Drug Monit. 13:1991;314-317.
55. Cloyd J.C., Kriel R.L., Fischer J.H., Sawchuk R.J., Eggerth R.M. Pharmacokinetics of valproic acid in children: I.@, multiple antiepileptic drug therapy. Neurology. 33:1983;185-191.
56. Schmucker D.L. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 18:2001;837-851.
57. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 23:1998;247-255.
58. Salem S.A., Rajjayabun P., Shepherd A.M., Stevenson I.H. Reduced induction of drug metabolism in the elderly. Age Ageing. 7:1978;68-73.
59. Twum-Barima Y., Finnigan T., Habash A.I., Cape R.D., Carruthers S.G. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol. 17:1984;595-597.
60. Battino D, Croci D, Mamoli D, Messina S, Rossini A, Perucca E. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia (in press).
61. Parker B.M., Cusack B.J., Vestal R.E. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging. 7:1995;10-18.
62. Perucca E., Dulac O., Shorvon S., Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs. 15:2001;609-621.
63. May T., Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. Ther Drug Monit. 7:1985;387-390.
64. Perucca E., Gatti G., Frigo G.M., Crema A., Calzetti S., Visintini D. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol. 5:1978;495-499.
65. Cloyd J.C., Dutta S., Cao G., et al. The Depacon Study Group. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 53:2003;19-27.
66. Samara E.E., Gustavson L.E., El-Shourbagy T., Locke C., Granneman G.R., Sommerville K.W. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia. 39:1998;868-873.
67. Giaccone M., Bartoli A., Gatti G., et al. Effects of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 41:1996;575-579.
68. May T.W., Rambeck B., Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 18:1996;523-531.
69. Bartoli A., Guerrini R., Belmonte A., Alessandri M.G., Gatti G., Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlation with clinical response. Ther Drug Monit. 19:1997;252-260.
70. Armijo J.A., Bravo J., Cuadrado A., Herranz J.L. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit. 21:1999;182-190.
71. Gidal B.E. Topiramate. Drug interactions. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. Antiepileptic Drugs. 5th edn:2002;734-739 Lippincott Williams and Wilkins, Philadelphia
72. Ojemann L.M., Shastri R.A., Wilenski A.J., et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit. 8:1986;293-296.
73. Tartara A., Galimberti C.A., Manni R., et al. The pharmacokinetic profile of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol. 36:1993;366-368.
74. Wagner M., Graves N.M., Marineau K., Holmes G.B., Remmel R.P., Leppik I.E. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia. 32:1991;398-406.
75. Khoo K.C., Mendels J., Rothbert M., et al. Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clin Pharmacol Ther. 28:1980;368-375.
76. Sennoune S., Mesdjian E., Bonneton J., Genton P., Dravet C., Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit. 14:1992;269-274.
77. Johannessen S.I., Strandjord R.E. Concentration of carbamazepine (Tegretol) in serum and cerebrospinal fluid in patients with epilepsy. Epilepsia. 14:1973;373-379.
78. Christiansen J., Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand. 49:1973;543-546.
79. Tomson T., Spina E., Wedlund J.E. Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy. Ther Drug Monit. 9:1987;117-119.
80. May T.W., Rambeck B., Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 21:1999;175-181.
81. Besag F.M., Berry D.J., Pool R. Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. Epilepsia. 41:2000;624-627.
82. Cloyd J.C., Miller K.W., Leppik I.E. Primidone kinetics: effects of concurrent drugs and duration of therapy. Clin Pharmacol Ther. 29:1981;402-407.
83. Kondo T., Kaneko S., Otani K., et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia. 33:1992;172-177.
84. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 38:2000;191-204.
85. Johannessen SI, Bettino D, Berry DJ, et al. Therapeutic drug monitoring of the new antiepileptic drugs. Ther Drug Monit (in press).
86. Radulovic L.L., Wilder B.J., Leppik I.E., et al. Lack of interaction of gabapentin with carbamazepine and valproate. Epilepsia. 35:1994;155-161.
87. Richens A. Pharmacology and clinical pharmacology of vigabatrin. J Child Neurol. 6:1991;2S7-2S10.
88. Patsalos P.N., Duncan J.S. The pharmacology and pharmacokinetics of vigabatrin. Rev Contemp Pharmacother. 6:1995;447-456.
89. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Therapeut. 85:2000;77-85.
90. Posner J., Webster H., Yuen A.W.C. Investigation of the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes. Br J Clin Pharmacol. 32:1991;658P.
91. Patsalos P.N. The pharmacokinetic profile of topiramate. Rev Contemp Pharmacother. 10:1999;155-162.
92. Gustavson L.E., Mengel H.B. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 36:1995;605-611.
93. Wang X.L., Patsalos P.N. The pharmacokinetic profile of tiagabine. Rev Contemp Pharmacother. 12:2002;225-233.
94. Mather G.C., Shah J. Zonisamide. Drug interactions. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. Antiepileptic drugs. 5th edn:2002;881-884 Lippincott Williams and Wilkins, Philadelphia.
95. Wnuk W., Volanski A., Foletti G. Topiramate decreases lamotrigine concentrations. Ther Drug Monit. 21:1999;449.
96. Berry D.J., Besac F.M., Pool F., Natarajan J., Doose D. Lack of an effect of topiramate on lamotrigine serum concentrations. Epilepsia. 43:2002;818-823.
97. Albani F., Theodore W.H., Washington P., et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia. 32:1991;130-132.
98. Rimmer E.M., Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol. 27:1989;27S-33S.
99. Tonini M., Gatti G., Manzo L., Olibet G., Coccini T., Perucca E. Vigabatrin does not affect the intestinal absorption of phenytoin in rat duodeno-jejunal loops in situ. Pharmacol Res. 26:1992;201-205.
100. Gatti G., Bartoli A., Marchiselli R., et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol. 36:1993;603-606.
101. Kapetanovic I.M., Kupferberg H.J., Porter R.J., Theodore W., Schulman E., Penry J.K. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 29:1981;480-486.
102. Yuen A.W.C., Land G., Weatherley B., Peck A.W. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol. 33:1992;511-513.
103. Binnie C.D., Van Emde Boas W., Kasteleijn Nolste Trenite D.G., et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia. 27:1986;248-254.
104. Gidal B.E., Anderson G.D., Rutecki P.R., Shaw R., Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res. 42:2000;23-31.
105. Dhillon S., Richens A. Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol. 13:1982;553-560.
106. Samara E.E., Granneman R.G., Witt G.F., Cavanaugh J.H. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacology. 37:1997;442-450.
107. Pisani F., Caputo M., Fazio A., et al. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia. 31:1990;339-342.
108. McKee P.J., Blackshaw J., Butler E., Gilham R.A., Brodie M.J. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 11:1992;193-198.
109. Rambeck B., May T., Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 9:1987;298-303.
110. Pisani F., Fazio A., Oteri G., et al. Sodium valproate and valpromide: Differential interactions with carbamazepine in epileptic patients. Epilepsia. 27:1986;548-552.
111. Lambie D.G., Johnson R. The effects of phenytoin on phenobarbitone and primidone metabolism. J Neurol Neurosurg Psychiat. 44:1981;148-151.
112. Windorfer A., Sauer W. Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepine and dipropylacetate. Neuropediatrie. 8:1977;29-41.
113. Diamond W., Buchanan R. A clinical study of the effect of phenobarbital on diphenylhydantoin plasma levels. J Clin Pharmacol. 10:1970;306-311.
114. Perucca E., Richens A. Antiepileptic drug interactions. Frey H.H., Janz D. Antiepileptic drugs, handbook of experimental pharmacology. 74:1985;831-855 Springer-Verlag, Berlin.
115. Rambeck B. Antiepileptic drug interactions in polytherapy. Epileptologia. 2:1998;43-53.
116. Lakehal F., Wurden C.J., Kalhorn T.F., Levy R.H. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res. 52:2002;79-83.
117. Sachdeo R.C., Sachdeo S.K., Levy R.H., et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 43:2002;691-696.
118. Graves N.M., Holmes G.B., Fuerst R.H., Leppik I.E. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 30:1989;225-229.
119. Wagner M.L., Graves N.M., Leppik I.E., et al. The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther. 56:1994;494-502.
120. Reidenberg P., Glue P., Banfield C.R., et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther. 58:1995;279-287.
121. Contin M., Riva R., Albani F., Baruzzi A. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 21:1999;604-608.
122. Houghton G.W., Richens A. Inhibition of phenytoin metabolism by sulthiame in epileptic patients. Br J Clin Pharmacol. 1:1974;59-66.
123. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed. Epilepsia. 41:2000;1364-1374.
124. Rowan A.J., Meijer J.W.A., de Beer-Pawlikowski N., van der Geest P., Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol. 40:1983;797-802.
125. Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 40:1999;1141-1146.
126. Ferrie C.D., Robinson R.O., Knott C., Panayiotopoulos C.P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand. 91:1995;200-212.
127. 105 Study Group, Brodie M.J., Yuen A.W.C. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 26:1997;423-432.
128. Ferrie C.D., Panayiotopoulos C.P. Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure. 3:1994;157-159.
129. Reutens D.C., Duncan J.S., Patsalos P.N. Disabling tremor after lamotrigine with sodium valproate. Lancet. 342:1993;185-186.
130. Gupta A.K., Jeavons P.M. Complex partial seizures: EEG foci and response to carbamazepine and sodium valproate. J Neurol Neurosurg Psychiat. 48:1985;1010-1014.
131. Ketter T.A., Pazzaglia P.J., Post R.M. Synergy of carbamazepine and valproic acid in affective illness: a case report and review of the literature. J Clin Psychopharmacol. 12:1992;276-281.
132. Harden C.L., Zisfein J., Atos-Radzion C.E., et al. Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy. J Epilepsy. 6:1993;91-94.
133. 012 Study Group, Brodie M.J., Mumford J.P. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res. 34:1999;199-205.
134. Mireles R., Leppik I.E. Valproate and clonazepam comedication in patients with intractable epilepsy. Epilepsia. 26:1985;122-126.
135. Stolarek I., Blacklaw J., Forrest G., Brodie M.J. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiat. 57:1994;921-924.
136. Stephen L.J., Sills G.J., Brodie M.J. Lamotrigine and topiramate may be a useful combination. Lancet. 351:1998;958-959.
137. Pisani F., Oteri G., Antonino F., Di Perri R. Complete seizure control following gabapentin-lamotrigine combination. Epilepsia. 40:(suppl 2):1999;253-254.
138. Leach J.P., Brodie. Synergism with GABAergic drugs in refractory epilepsy. Lancet. 343:1994;1650.
139. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neur Scand. 162:(suppl 1):1995;31-34.
140. Shorvon S.D., Reynolds E.H. Reduction in polypharmacy for epilepsy. BMJ. 27:1979;1023-1025.
141. Perucca E. Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res. 52:2002;25-33.
142. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia. 39:1998;5-17.
143. Besag F.M.C., Berry D.J., Pool F., Newbery J.E., Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 39:1998;183-187.
144. Sackellares J.C., Lee S.I., Dreifuss F.E. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia. 20:1979;697-703.